지혈제 및 조직용 실란트 시장 : 제품 유형, 재료 유형, 용도, 최종사용자별 - 세계 예측(2025-2030년)

The Hemostats & Tissue Sealants Market was valued at USD 6.85 billion in 2024 and is projected to grow to USD 7.69 billion in 2025, with a CAGR of 12.36%, reaching USD 13.79 billion by 2030.

Introduction

The landscape of hemostats and tissue sealants is witnessing compelling evolution, energized by advances in medical technology and shifts in clinical practices. Over recent years, the global market for these critical surgical adjuncts has grown alongside increasing demand for safe and effective surgical interventions. This report explores how innovation, evolving patient needs, and regulatory developments converge to shape the market and redefine competitive strategies. It provides insights into the intricate dynamics that influence product development, deployment, and adoption across diverse clinical settings. In an era marked by heightened scrutiny on surgical outcomes and patient safety, stakeholders-from product developers to end users-are focused on achieving precision, efficiency, and cost-effectiveness. The discussion that follows delivers a comprehensive perspective on key market drivers and the strategic approaches that are fueling expansion, opening new avenues for collaboration, and offering improved clinical outcomes. Engaging with the analysis in the forthcoming sections, readers are prepared to navigate a market determined by both technological breakthroughs and enduring clinical traditions.

Transformative Shifts in the Landscape

Recent industry transformations have redefined the hemostats and tissue sealants market. Emerging technological innovations, such as bioengineered materials and refined manufacturing techniques, have dramatically increased product performance and reliability. There is a pronounced shift in operational procedures within hospitals and clinics. New regulatory policies and evolving reimbursement frameworks are ensuring that product development is closely aligned with patient safety and quality assurance. Enhanced imaging technologies and the integration of digital tools into surgical settings are enabling practitioners to apply these products more precisely, reducing complications and improving recovery times. In parallel, strategic collaborations between key suppliers and research institutions have accelerated product innovation, offering breakthroughs that address past limitations in hemostasis and wound sealing. The role of data analytics in monitoring real-time outcomes has provided actionable insights for fine-tuning product applications, thereby fostering an environment where continuous improvement meets clinical necessity. This period of dynamic change calls for companies to embrace new distribution models, incorporate evidence-based research into their product development life cycles, and remain adaptive in the face of market consolidation and regulatory evolution.

Key Segmentation Insights

A granular examination of market segmentation reveals differentiated opportunities across product, material, application, and end-user categories. When viewed through the lens of product type, the market is distinctly categorized into the realms of hemostats and tissue sealants. The hemostats segment evidences further division into active, flowable, and mechanical variants, each offering nuanced benefits that address different clinical demands, while tissue sealants are essentially bifurcated into fibrin sealants and synthetic sealants. Diving deeper, material type segmentation highlights a dichotomy between natural and synthetic materials. Natural materials themselves are further differentiated based on their bovine-derived and human-derived origins, contrasted against synthetic counterparts which, in turn, break down into collagen-based and polymer-based formulations. Application-based segmentation offers insights into usage across both non-surgical and surgical procedures; the former encompasses diagnostic procedures and minor wound sealing where minimally invasive techniques are predominant, while the latter is subdivided into cardiovascular surgery, gastrointestinal surgery, and general surgery, each of which poses unique technical and regulatory challenges. Finally, end-user segmentation is defined by operational settings that range from ambulatory surgical centers and clinics to hospitals, each environment presenting distinct requirements and opportunities. These layered segmentation frameworks provide a foundation for developing tailored strategies that address each niche's market potential without sacrificing the broader scope of innovation that the industry demands.

Based on Product Type, market is studied across Hemostats and Tissue Sealants. The Hemostats is further studied across Active Hemostats, Flowable Hemostats, and Mechanical Hemostats. The Tissue Sealants is further studied across Fibrin Sealants and Synthetic Sealants.

Based on Material Type, market is studied across Natural Materials and Synthetic Materials. The Natural Materials is further studied across Bovine-Derived and Human-Derived. The Synthetic Materials is further studied across Collagen-Based and Polymer-Based.

Based on Application, market is studied across Non-Surgical Procedures and Surgical Procedures. The Non-Surgical Procedures is further studied across Diagnostic Procedures and Minor Wound Sealing. The Surgical Procedures is further studied across Cardiovascular Surgery, Gastrointestinal Surgery, and General Surgery.

Based on End User, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals.

Key Regional Insights

Geographical insights into the market further delineate where opportunities and challenges converge. In the Americas, a mature market environment is characterized by advanced healthcare infrastructure, rigorous regulatory frameworks, and high adoption rates of innovative surgical products. The region's focus on enhancing patient safety and improving surgical outcomes has created fertile ground for both established and emerging companies. In contrast, the combined regions of Europe, Middle East & Africa present a mix of mature markets and emerging economies, where regulatory harmonization efforts play a pivotal role in fostering innovation while addressing regional disparities in healthcare access. The Europe sector benefits from strong research and development investments and a supportive policy environment, while the Middle East and Africa are rapidly evolving through government-led healthcare initiatives and regional collaborations. Meanwhile, the Asia-Pacific region is emerging as a high-growth market fueled by increasing healthcare expenditure, expanding medical infrastructure, and an ever-growing patient base. Rapid urbanization and robust economic growth have boosted investments in advanced medical technologies, ensuring that product portfolios in this category are frequently updated to reflect international standards. In this context, understanding regional nuances is essential for stakeholders aiming to position their offerings effectively across diverse regulatory and cultural landscapes.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

Analysis of leading entities within the hemostats and tissue sealants domain provides an understanding of competitive strategies and market positioning. Leaders such as Abbott Laboratories, Advanced Medical Solutions Group PLC, and Aegis Lifesciences Private Limited have distinguished themselves by focusing on innovative product design and strategic geographic expansion. Iconic entities like B. Braun SE, Baxter International Inc., and Becton, Dickinson and Company harness their substantial R&D investments to continually enhance product portfolios and improve clinical outcomes. Further, companies like Cardinal Health, CooperSurgical, and CryoLife have demonstrated a commitment to integrating advanced technologies with robust clinical data, driving new standards of care. Firms such as CSL Behring and CuraMedical B.V. excel in merging quality with regulatory excellence, while innovators like Grifols and Hemostasis, LLC deliver cutting-edge approaches to patient care that redefine traditional boundaries. Esteemed market players Hologic, Integra LifeSciences Corporation, and Johnson & Johnson Services, Inc. maintain a sharp strategic focus on expanding their global footprint through dedicated investments in key clinical segments. The competitive landscape is also enriched by contributions from multinational corporations such as KAKEN PHARMACEUTICAL CO., LTD., KATSAN Katgut Sanayi ve Tic. A.S., Medline Industries, and Medtronic PLC, each enhancing the sector's diversity. Additional prominent players, including Olympus Corporation, Owens & Minor, Pfizer, Smith & Nephew PLC, Stryker Corporation, Teleflex Incorporated, Terumo Corporation, Thermo Fisher Scientific Inc., Vivostat A/S, and Zimmer Biomet, fortify their market positions by leveraging their extensive global networks and diversified product strategies. The synthesis of these companies' strategies underscores a relentless pursuit of innovation and excellence, setting benchmarks that drive industry-wide progress.

The report delves into recent significant developments in the Hemostats & Tissue Sealants Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Advanced Medical Solutions Group PLC, Aegis Lifesciences Private Limited., B. Braun SE, Baxter International Inc., Becton, Dickinson and Company, Cardinal Health, Inc., CooperSurgical, Inc., CryoLife, Inc., CSL Behring, CuraMedical B.V., Grifols, S.A., Hemostasis, LLC, Hologic, Inc., Integra LifeSciences Corporation, Johnson & Johnson Services, Inc., KAKEN PHARMACEUTICAL CO., LTD., KATSAN Katgut Sanayi ve Tic. A.S., Medline Industries, LP., Medtronic PLC, Olympus Corporation, Owens & Minor, Pfizer, Inc., Smith & Nephew PLC, Stryker Corporation, Teleflex Incorporated, Terumo Corporation, Thermo Fisher Scientific Inc., Vivostat A/S, and Zimmer Biomet. Actionable Recommendations for Industry Leaders

Industry leaders must pursue a multipronged strategic approach to fully harness the emerging opportunities within the hemostats and tissue sealants market. Firstly, emphasizing research and development is paramount, with a specific focus on next-generation materials and advanced manufacturing processes that can deliver superior performance in clinical settings. Companies are advised to engage more deeply with academic and clinical institutions to validate innovative product concepts through rigorous trials and evidence-based studies. Strategic collaborations and partnerships can further accelerate product development and market penetration, especially in regions where regulatory landscapes and consumer expectations differ markedly. It is equally important to invest in digital transformation initiatives that streamline supply chains and optimize operational efficiency, enabling a quicker time-to-market for novel products. Additionally, market leaders should refine their segmentation strategies, ensuring that products are tailored to meet the specific needs of diverse clinical applications. This means effectively addressing the demands of non-surgical procedures such as diagnostic and minor wound sealing, alongside more complex surgical interventions like cardiovascular, gastrointestinal, and general surgeries. By developing integrated solutions that cater to the needs of both ambulatory surgical centers and hospital environments, companies can offer a comprehensive product portfolio. Finally, it is crucial to remain agile in the face of evolving regulatory frameworks and market dynamics, thereby ensuring sustained competitive advantage and robust growth trajectories over the long term.

Conclusion

The hemostats and tissue sealants market stands at the forefront of a transformative era in medical technology and surgical care. As the industry evolves, companies must adopt innovative strategies that integrate advanced material science, precise clinical applications, and region-specific market dynamics. The insights shared here illuminate a landscape where precise segmentation, proactive regional focus, and strategic consolidation among leading players are driving significant advancements. The fusion of technological innovation and rigorous clinical research is not only redefining product standards but also paving the way for safer, more efficient surgical outcomes. Stakeholders who capitalize on these trends are likely to secure a competitive edge, leveraging the convergence of emerging technologies and proven clinical practices to come out ahead in an increasingly competitive global market. In summary, a forward-thinking approach that prioritizes research, collaborative innovation, and agile market adaptation is essential for sustained success in this evolving arena.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of chronic disorders and need for timely surgeries
    • 5.1.1.2. Rising demand for minimally invasive surgeries among patients
    • 5.1.1.3. Favorable reimbursement policies for surgical interventions
  • 5.1.2. Restraints
    • 5.1.2.1. Low outlining quality and high costs of surgical sealants
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of customized hemostatic and sealing solutions for specific wounds
    • 5.1.3.2. Ongoing innovations in eco-friendly hemostat and sealant solutions
  • 5.1.4. Challenges
    • 5.1.4.1. Strict standards regarding the utilization of hemostats & tissue sealants
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product Type: Rising significance of synthetic sealants owing to their prolonged shelf life and reliability
  • 5.2.2. Application: Expanding application of hemostats and tissue sealants among non-surgical procedures
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Hemostats & Tissue Sealants Market, by Product Type

• 6.1. Introduction
• 6.2. Hemostats
  • 6.2.1. Active Hemostats
  • 6.2.2. Flowable Hemostats
  • 6.2.3. Mechanical Hemostats
• 6.3. Tissue Sealants
  • 6.3.1. Fibrin Sealants
  • 6.3.2. Synthetic Sealants

7. Hemostats & Tissue Sealants Market, by Material Type

• 7.1. Introduction
• 7.2. Natural Materials
  • 7.2.1. Bovine-Derived
  • 7.2.2. Human-Derived
• 7.3. Synthetic Materials
  • 7.3.1. Collagen-Based
  • 7.3.2. Polymer-Based

8. Hemostats & Tissue Sealants Market, by Application

• 8.1. Introduction
• 8.2. Non-Surgical Procedures
  • 8.2.1. Diagnostic Procedures
  • 8.2.2. Minor Wound Sealing
• 8.3. Surgical Procedures
  • 8.3.1. Cardiovascular Surgery
  • 8.3.2. Gastrointestinal Surgery
  • 8.3.3. General Surgery

9. Hemostats & Tissue Sealants Market, by End User

• 9.1. Introduction
• 9.2. Ambulatory Surgical Centers
• 9.3. Clinics
• 9.4. Hospitals

10. Americas Hemostats & Tissue Sealants Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Hemostats & Tissue Sealants Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Hemostats & Tissue Sealants Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2024
• 13.2. FPNV Positioning Matrix, 2024
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Medcura secures USD 4 million funding to innovate life-saving battlefield hemostats
  • 13.3.2. Grifols expands pediatric surgical care with FDA-approved fibrin sealant enhancing hemostasis outcomes
  • 13.3.3. Teleflex expands market reach with Premier, Inc. through competitive hemostasis product agreements
  • 13.3.4. Olympus Launches EndoClot Hemostatic Agents and Submucosal Injection Agent in European Markets
  • 13.3.5. Corza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing Operations
  • 13.3.6. Advamedica Inc Announces FDA Clearance for Ax-Surgi Surgical Hemostat
  • 13.3.7. Team Develops Extracellular Matrix-Based Sticky Sealants For Corneal Tissue Reconstruction
  • 13.3.8. Medcura Receives Breakthrough Device Designation for its LifeGel(TM) Absorbable Surgical Hemostat
  • 13.3.9. Cresilon Closes $25 Million in Series A-4 Financing to Accelerate Global Expansion and Bring Revolutionary Hemostatic Gel to Human Health Market
  • 13.3.10. ZEISS Receives FDA Clearance for MTLawton - A New Generation of Bipolar Forceps for Electrosurgery
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Advanced Medical Solutions Group PLC
• 3. Aegis Lifesciences Private Limited.
• 4. B. Braun SE
• 5. Baxter International Inc.
• 6. Becton, Dickinson and Company
• 7. Cardinal Health, Inc.
• 8. CooperSurgical, Inc.
• 9. CryoLife, Inc.
• 10. CSL Behring
• 11. CuraMedical B.V.
• 12. Grifols, S.A.
• 13. Hemostasis, LLC
• 14. Hologic, Inc.
• 15. Integra LifeSciences Corporation
• 16. Johnson & Johnson Services, Inc.
• 17. KAKEN PHARMACEUTICAL CO., LTD.
• 18. KATSAN Katgut Sanayi ve Tic. A.S.
• 19. Medline Industries, LP.
• 20. Medtronic PLC
• 21. Olympus Corporation
• 22. Owens & Minor
• 23. Pfizer, Inc.
• 24. Smith & Nephew PLC
• 25. Stryker Corporation
• 26. Teleflex Incorporated
• 27. Terumo Corporation
• 28. Thermo Fisher Scientific Inc.
• 29. Vivostat A/S
• 30. Zimmer Biomet